Zhi Tong Cai Jing·2025-08-24 22:55Core Insights - The company reported a revenue of RMB 286.04 billion for the first half of 2025, representing a year-on-year decrease of 2.95% [1] - Net profit attributable to shareholders was RMB 3.47 billion, down 6.43% year-on-year, with earnings per share at RMB 1.11 [1] - The company is focusing on stable recovery and sustainable business development amidst a rapidly changing policy and market environment [1] Revenue Breakdown - The pharmaceutical distribution segment maintained stable development, with its revenue share decreasing by 0.48 percentage points to 73.62% [1] - The medical device distribution segment saw a slight increase in revenue share by 0.08 percentage points to 19.22%, despite a decline in revenue scale [1] - The pharmaceutical retail segment experienced growth, with its revenue share increasing by 0.36 percentage points to 5.78% [1] Cost Management - The company demonstrated effective cost control during the reporting period, benefiting from reduced financing costs, integrated management measures, and lower business costs [2] - The sales expense ratio, management expense ratio, and financial expense ratio decreased to 2.74%, 1.28%, and 0.35% respectively, collectively optimizing by 0.2 percentage points [2] - These improvements in expense ratios provided strong support for mitigating profit decline [2]